Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
10.41
-0.65 (-5.88%)
At close: Mar 11, 2026, 4:00 PM EDT
10.27
-0.14 (-1.34%)
After-hours: Mar 11, 2026, 5:10 PM EDT
Zevra Therapeutics Employees
Zevra Therapeutics had 59 employees as of December 31, 2024. The number of employees decreased by 10 or -14.49% compared to the previous year.
Employees
59
Change (1Y)
-10
Growth (1Y)
-14.49%
Revenue / Employee
$1,804,576
Profits / Employee
$1,315,000
Market Cap
611.19M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 59 | -10 | -14.49% | 59 | 0 |
| Dec 31, 2023 | 69 | 33 | 91.67% | 65 | 4 |
| Dec 31, 2022 | 36 | 12 | 50.00% | 32 | 4 |
| Dec 31, 2021 | 24 | 2 | 9.09% | 24 | 0 |
| Dec 31, 2020 | 22 | 0 | - | 22 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| ADC Therapeutics | 265 |
| Rigel Pharmaceuticals | 164 |
| Prothena Corporation | 163 |
| Century Therapeutics | 150 |
| CorMedix | 65 |
| Altimmune | 59 |
| Fulcrum Therapeutics | 55 |
ZVRA News
- 1 day ago - Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model - Seeking Alpha
- 1 day ago - Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call - GlobeNewsWire
- 14 days ago - Zevra Therapeutics to Present at the Citizens Life Sciences Conference - GlobeNewsWire
- 15 days ago - Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer - GlobeNewsWire
- 20 days ago - Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Newsfile Corp
- 5 weeks ago - Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ - GlobeNewsWire
- 5 weeks ago - Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 - GlobeNewsWire